
Stephen R Marder

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7318520/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Antipsychotic discontinuation and recovery: chicken or egg?. Psychological Medicine, 2023, 53, 1134-1135.	4.5	3
2	Motivational and cognitive factors linked to community integration in homeless veterans: study 1 – individuals with psychotic disorders. Psychological Medicine, 2022, 52, 169-177.	4.5	4
3	Examining racial differences in community integration between black and white homeless veterans. Psychiatry Research, 2022, 308, 114385.	3.3	2
4	Assessment of Negative Symptoms in Clinical Trials of Acute Schizophrenia: Test of a Novel Enrichment Strategy. Schizophrenia Bulletin Open, 2022, 3, .	1.7	6
5	Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature, 2022, 604, 502-508.	27.8	929
6	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. Pharmacopsychiatry, 2022, 55, 73-86.	3.3	107
7	Comparative risks of all-cause mortality for Veterans with schizophrenia with ongoing receipt of clozapine and other antipsychotic medications. Psychiatry Research, 2022, 313, 114590.	3.3	1
8	A long-term, open-label study of valbenazine for tardive dyskinesia. CNS Spectrums, 2021, 26, 345-353.	1.2	2
9	Stigma—Personal Views. Schizophrenia Bulletin, 2021, 47, 1-2.	4.3	0
10	Onset and Resolution of Key Adverse Events in Valbenazine-Treated Patients with Tardive Dyskinesia: Pooled Analyses from Two Long-Term Clinical Trials. CNS Spectrums, 2021, 26, 151-151.	1.2	0
11	Changing the Face of Schizophrenia. American Journal of Psychiatry, 2021, 178, 584-585.	7.2	1
12	PANSS Individual Item and Marder Dimension Analyses From a Pivotal Trial of RBP-7000 (Monthly) Tj ETQq0 0 0	rgBT /Over 2.2	lock 10 Tf 50
13	Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies. Schizophrenia Bulletin Open, 2021, 2, sgab014.	1.7	2
14	Contributions of common genetic variants to risk of schizophrenia among individuals of African and Latino ancestry. Molecular Psychiatry, 2020, 25, 2455-2467.	7.9	82
15	The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. NPJ Schizophrenia, 2020, 6, 1.	3.6	193
16	139 Early Response with Valbenazine and Long-Term Symptom Reduction in Patients with Tardive Dyskinesia: Post Hoc Analysis of the KINECT 3 Study. CNS Spectrums, 2020, 25, 288-289.	1.2	0

17	140 Effects of Long-Term Valbenazine on Tardive Dyskinesia in KINECT 4: Post Hoc Response and Shift Analyses. CNS Spectrums, 2020, 25, 289-289.	1.2	0
18	Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizzophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and	5.4	32

pharmacoBOLD in healthy volunteers. Neuropsychopharmacology, 2020, 45, 1842-1850.

#	Article	IF	CITATIONS
19	<i>Post hoc</i> analysis of a randomised, placebo-controlled, active-reference 6-week study of brexpiprazole in acute schizophrenia. Acta Neuropsychiatrica, 2020, 32, 153-158.	2.1	7
20	lssues and Perspectives in Designing Clinical Trials for Negative Symptoms in Schizophrenia: Consensus Statements. Schizophrenia Bulletin Open, 2020, 1, .	1.7	5
21	123 Long-Term Outcomes with Valbenazine 40 mg/day in Adults With Tardive Dyskinesia. CNS Spectrums, 2020, 25, 279-280.	1.2	0
22	Introducing Schizophrenia Bulletin Open. Schizophrenia Bulletin Open, 2020, 1, .	1.7	0
23	The Neurobiology of Treatment-Resistant Schizophrenia: Paths to Antipsychotic Resistance and A Roadmap for Future Research. Focus (American Psychiatric Publishing), 2020, 18, 456-465.	0.8	8
24	Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice. Journal of Clinical Psychiatry, 2020, 81, .	2.2	86
25	A dose-finding study of oxytocin using neurophysiological measures of social processing. Neuropsychopharmacology, 2019, 44, 289-294.	5.4	28
26	Evaluating visual neuroplasticity with EEG in schizophrenia outpatients. Schizophrenia Research, 2019, 212, 40-46.	2.0	17
27	39 Long-term Safety and Tolerability of Once-Daily Valbenazine in Patients with Tardive Dyskinesia. CNS Spectrums, 2019, 24, 196-196.	1.2	0
28	77 Long-term Valbenazine Treatment in Patients with Schizophrenia/Schizoaffective Disorder or Mood Disorder and Tardive Dyskinesia. CNS Spectrums, 2019, 24, 214-215.	1.2	2
29	38 Global Improvement and Patient Satisfaction: Results from a Long-term, Open-label, Rollover Study of Valbenazine in Tardive Dyskinesia. CNS Spectrums, 2019, 24, 195-196.	1.2	0
30	History of Psychopharmacology. Annual Review of Clinical Psychology, 2019, 15, 25-50.	12.3	51
31	A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia. Journal of Clinical Psychopharmacology, 2019, 39, 620-627.	1.4	20
32	Contribution of Rare Copy Number Variants toÂBipolar Disorder Risk Is Limited to Schizoaffective Cases. Biological Psychiatry, 2019, 86, 110-119.	1.3	45
33	Parsing components of auditory predictive coding in schizophrenia using a roving standard mismatch negativity paradigm. Psychological Medicine, 2019, 49, 1195-1206.	4.5	24
34	Understanding the Association Between Negative Symptoms and Performance on Effort-Based Decision-Making Tasks: The Importance of Defeatist Performance Beliefs. Schizophrenia Bulletin, 2018, 44, 1217-1226.	4.3	32
35	The Importance of Adequately Powered Clinical Studies: Response to Khan et al American Journal of Psychiatry, 2018, 175, 188-189.	7.2	1
36	The effects of curcumin on brain-derived neurotrophic factor and cognition in schizophrenia: A randomized controlled study. Schizophrenia Research, 2018, 195, 572-573.	2.0	28

#	Article	IF	CITATIONS
37	A 10-minute measure of global cognition: Validation of the Brief Cognitive Assessment Tool for Schizophrenia (B-CATS). Schizophrenia Research, 2018, 195, 327-333.	2.0	17
38	Reliability and validity of the self-report version of the apathy evaluation scale in first-episode Psychosis: Concordance with the clinical version at baseline and 12 months follow-up. Psychiatry Research, 2018, 267, 140-147.	3.3	13
39	Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies. Acta Neuropsychiatrica, 2017, 29, 278-290.	2.1	22
40	Improving measurement of attributional style in schizophrenia; A psychometric evaluation of the Ambiguous Intentions Hostility Questionnaire (AIHQ). Journal of Psychiatric Research, 2017, 89, 48-54.	3.1	40
41	The current conceptualization of negative symptoms in schizophrenia. World Psychiatry, 2017, 16, 14-24.	10.4	354
42	A Cruel Irony for Clinicians Who Treat Depression. American Journal of Psychiatry, 2017, 174, 409-410.	7.2	1
43	Bitopertin in Negative Symptoms of Schizophrenia—Results From the Phase III FlashLyte and DayLyte Studies. Biological Psychiatry, 2017, 82, 8-16.	1.3	92
44	Why Are Innovative Drugs Failing in Phase III?. American Journal of Psychiatry, 2017, 174, 829-831.	7.2	16
45	How Occupationally High-Achieving Individuals With a Diagnosis of Schizophrenia Manage Their Symptoms. Psychiatric Services, 2017, 68, 324-329.	2.0	15
46	An RCT Evaluating the Effects of Skills Training and Medication Type on Work Outcomes Among Patients With Schizophrenia. Psychiatric Services, 2017, 68, 271-277.	2.0	20
47	Older Brains are Different: Brain–Behavior Studies and Their Clinical Utility. American Journal of Geriatric Psychiatry, 2017, 25, 11-12.	1.2	7
48	Task-related fMRI responses to a nicotinic acetylcholine receptor partial agonist in schizophrenia: A randomized trial. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 71, 66-75.	4.8	8
49	Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research. Biological Psychiatry, 2016, 80, 84-86.	1.3	2
50	Novel Treatments of Psychosis. Current Behavioral Neuroscience Reports, 2015, 2, 119-126.	1.3	0
51	Effort-Based Decision-Making Paradigms for Clinical Trials in Schizophrenia: Part 1—Psychometric Characteristics of 5 Paradigms. Schizophrenia Bulletin, 2015, 41, 1045-1054.	4.3	137
52	SchizophreniaTime to Commit to Policy Change. Schizophrenia Bulletin, 2014, 40, S165-S194.	4.3	153
53	Restrictive symptomatic inclusion criteria create barriers to clinical research in schizophrenia negative symptoms: An analysis of the CATIE dataset. European Neuropsychopharmacology, 2014, 24, 1615-1621.	0.7	5
54	The Reliability and Validity of the MATRICS Functional Assessment Battery. Schizophrenia Bulletin, 2014, 40, 1047-1052.	4.3	21

#	Article	IF	CITATIONS
55	Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms. Psychiatry Research, 2014, 218, 219-224.	3.3	23
56	lssues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophrenia Research, 2013, 150, 328-333.	2.0	46
57	Pharmacological approaches to treating negative symptoms: A review of clinical trials. Schizophrenia Research, 2013, 150, 346-352.	2.0	80
58	Apathy, poor verbal memory and male gender predict lower psychosocial functioning one year after the first treatment of psychosis. Psychiatry Research, 2013, 210, 55-61.	3.3	52
59	Adapting Social Neuroscience Measures for Schizophrenia Clinical Trials, Part 3: Fathoming External Validity. Schizophrenia Bulletin, 2013, 39, 1211-1218.	4.3	36
60	Adapting Social Neuroscience Measures for Schizophrenia Clinical Trials, Part 2: Trolling the Depths of Psychometric Properties. Schizophrenia Bulletin, 2013, 39, 1201-1210.	4.3	70
61	Clinician Perceptions, Expectations, and Management of Negative Symptoms in Schizophrenia. Journal of Clinical Psychiatry, 2013, 74, e01.	2.2	6
62	Monitoring Treatment and Managing Adherence in Schizophrenia. Journal of Clinical Psychiatry, 2013, 74, e21.	2.2	12
63	The Brief Negative Symptom Scale: Psychometric Properties. Schizophrenia Bulletin, 2011, 37, 300-305.	4.3	653
64	Methodological Issues in Negative Symptom Trials. Schizophrenia Bulletin, 2011, 37, 250-254.	4.3	67
65	2010 Wayne Fenton Award for Exceptional Clinical Care: The Wayne Fenton Award for Exceptional Clinical Care was established in 2007 to recognize clinical providers who exemplify Dr. Fenton's commitment to improving the daily lives of individuals with schizophrenia Schizophrenia Bulletin, 2010, 36, 891-892.	4.3	0
66	Apathy in first episode psychosis patients: One year follow up. Schizophrenia Research, 2010, 116, 20-26.	2.0	72
67	The Acute Efficacy of Aripiprazole Across the Symptom Spectrum of Schizophrenia. Journal of Clinical Psychiatry, 2009, 70, 25-35.	2.2	37
68	Sex, Race, and Smoking Impact Olanzapine Exposure. Journal of Clinical Pharmacology, 2008, 48, 157-165.	2.0	146
69	The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The Efficacy of Glutamatergic Agents for Negative Symptoms and Cognitive Impairments. American Journal of Psychiatry, 2007, 164, 1593-1602.	7.2	377
70	The NIMH MATRICS Initiative: Development of a Consensus Cognitive Battery. Progress in Neurotherapeutics and Neuropsychopharmacology, 2007, 2, 173-186.	0.0	3
71	Aripiprazole Effects in Patients With Acute Schizophrenia Experiencing Higher or Lower Agitation. Journal of Clinical Psychiatry, 2007, 68, 662-668.	2.2	25
72	The NIMH-MATRICS Consensus Statement on Negative Symptoms. Schizophrenia Bulletin, 2006, 32, 214-219.	4.3	1,081

#	Article	IF	CITATIONS
73	The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia. Dialogues in Clinical Neuroscience, 2006, 8, 109-113.	3.7	62
74	Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophrenia Research, 2003, 61, 123-136.	2.0	449
75	Maintenance Treatment of Schizophrenia With Risperidone or Haloperidol: 2-Year Outcomes. American Journal of Psychiatry, 2003, 160, 1405-1412.	7.2	85
76	A Compensatory Mirror Cortical Mechanism for Facial Affect Processing in Schizophrenia. Neuropsychopharmacology, 2001, 25, 915-924.	5.4	39
77	The Effects of Risperidone on the Five Dimensions of Schizophrenia Derived by Factor Analysis. Journal of Clinical Psychiatry, 1997, 58, 538-546.	2.2	629
78	Field dependent transverse relaxation rate increase may be a specific measure of tissue iron stores. Magnetic Resonance in Medicine, 1993, 29, 459-464.	3.0	159
79	The sulfoxidation of fluphenazine in schizophrenic patients maintained on fluphenazine decanoate. Psychopharmacology, 1987, 93, 369-373.	3.1	11
80	Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate. Psychopharmacology, 1986, 88, 480-483.	3.1	30
81	Antipsychotic Drugs. , 0, , 2161-2201.		18